TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38436998

Group type: EXPERIMENTAL
Intervention: Batoclimab (680 mg, subcutaneous injections, 6 weekly doses)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (matching placebo, 6 weekly doses)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Batoclimab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 38437013

Group type: EXPERIMENTAL
Intervention: Empower@Home (wCBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Attention control (friendly phone calls and depressive symptom monitoring)
Number of subjects: 70
Study: 38437204

Group type: EXPERIMENTAL
Intervention: Managerial position
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Cross-sectional and longitudinal analysis
Number of subjects: 704
Study: 38437238

Group type: EXPERIMENTAL
Intervention: Yathu Yathu (community-based, peer-led sexual and reproductive health services)
Number of subjects: 10974

Group type: EXPERIMENTAL
Intervention: Yathu Yathu
Number of subjects: 10974

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10974
Study: 38437633

Group type: EXPERIMENTAL
Intervention: Dedicated training programme to implement 10 quality of care measures to reduce LOS with an implementation phase of eight weeks.
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 1829
Study: 38437725

Group type: EXPERIMENTAL
Intervention: CD19-CD28 in combination with glofitamab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple combination of glofitamab with CD19-CD28 and CD19-4-1BBL
Number of subjects: 0
Study: 38437857

Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec (2×10^13 vg/kg)
Number of subjects: 54
Study: 38437868

Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the risk A allele (AA)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Posture activation of aldosterone
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Urinary excretion of aldosterone
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Caucasian females under 50 years with AA genotype
Number of subjects: 865

Group type: COMPARATOR
Intervention: African cohort
Number of subjects: 865
Study: 38437873

Group type: EXPERIMENTAL
Intervention: XR-BA (Extended Reality-Enhanced Behavioral Activation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional BA (Behavioral Activation)
Number of subjects: 26
Study: 38437926

Group type: EXPERIMENTAL
Intervention: In-person + app group (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Virtual + app group (n = 7)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-list, education-enhanced control group (n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All app participants
Number of subjects: 22
Study: 38437953

Group type: EXPERIMENTAL
Intervention: T-TEER (tricuspid transcatheter edge-to-edge repair)
Number of subjects: 186
Study: 38437986

Group type: EXPERIMENTAL
Intervention: Telemedicine group (TG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Face-to-face group (FFG)
Number of subjects: 50
Study: 38437999

Group type: EXPERIMENTAL
Intervention: Real-time computer-aided detection (CADe)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Traditional colonoscopy
Number of subjects: 1100
Study: 38438123

Group type: EXPERIMENTAL
Intervention: RTS,S full-dose regimen (2 full doses at months 0 and 1)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (one-fifth doses)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: RTS,S full-dose regimen (R012-14-26)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (Fx012-14-26)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (Fx017-20-32)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Rabies control vaccine
Number of subjects: 1500
Study: 38438427

Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine candidate (40 μg, two doses administered 28 days apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2 vaccine (30 μg, two doses administered 21 days apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine candidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2 vaccine
Number of subjects: 0
Study: 38438576

Group type: EXPERIMENTAL
Intervention: Physiotherapist led behaviour change intervention (4 sessions in 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (PA information leaflet only)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall study design and intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Physiotherapist led behaviour change intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Health care professionals and patient participants feedback
Number of subjects: 25
Study: 38438681

Group type: EXPERIMENTAL
Intervention: 10.5 mg bupivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 11.25 mg bupivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 12 mg bupivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 9.75 mg bupivacaine
Number of subjects: 42
Study: 38438707

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 936
Study: 38438735

Group type: EXPERIMENTAL
Intervention: Triplet arm (sintilimab, chidamide, and bevacizumab)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Doublet arm (sintilimab and chidamide)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 48
Study: 38438843

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration in home care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration in steady care situations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Means of communication (telephone, fax, e-mail)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personal acquaintance and mutual trust
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lack of mutual availability, limited time, and inadequate compensation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Joint collaborations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Complexity of healthcare situation
Number of subjects: 20
Study: 38438859

Group type: EXPERIMENTAL
Intervention: Function-based preventive intervention including functional examination and lifestyle counselling
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Functional examination consisting of 20 established tests and a sub-maximal ergometer test
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Risk profile based on functional examination
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Functional screening and lifestyle counselling
Number of subjects: 27
Study: 38438923

Group type: EXPERIMENTAL
Intervention: 50 μg roflumilast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 μg roflumilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38438945

Group type: EXPERIMENTAL
Intervention: Higher parental involvement in PA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Higher parental support for PA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Overall parental practices (involvement in PA + support for PA + control of screen viewing context)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Overall parental practices
Number of subjects: 425

Group type: COMPARATOR
Intervention: Parental control of screen viewing contexts and neighbourhood environmental factors
Number of subjects: 425
Study: 38439024

Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-based cord clamping (TBCC)
Number of subjects: 0
Study: 38439027

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.1~1.0 μg/kg/h for 24 h
Number of subjects: 368

Group type: COMPARATOR
Intervention: Saline (control) for 24 h
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 368
Study: 38439069

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index software
Number of subjects: 485
Study: 38439076

Group type: EXPERIMENTAL
Intervention: ROAD Home implementation strategy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stewardship as usual control
Number of subjects: 40
Study: 38439079

Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Alpelisib + Fulvestrant
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 505
Study: 38439092

Group type: EXPERIMENTAL
Intervention: Group Schema Therapy (GST)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy Enhanced (CBT-E)
Number of subjects: 232
Study: 38439113

Group type: EXPERIMENTAL
Intervention: Expect With Me group prenatal care
Number of subjects: 41
Study: 38439582

Group type: EXPERIMENTAL
Intervention: CA-125 tertile 3
Number of subjects: 1111

Group type: COMPARATOR
Intervention: CA-125 tertile 1
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Upper CA-125 tertile
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1111
Study: 38439783

Group type: EXPERIMENTAL
Intervention: Onchocerciasis-associated epilepsy (OAE) cases (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls without epilepsy (n=20)
Number of subjects: 40
Study: 38439933

Group type: EXPERIMENTAL
Intervention: BLS training with instructor feedback
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: BLS training with software-based feedback
Number of subjects: 360
Study: 38440046

Group type: EXPERIMENTAL
Intervention: Deep learning-based image processing workflow (One-Step PASI framework)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Deep learning model performance
Number of subjects: 2700
Study: 38440130

Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.6 mg/mL twice daily (BID)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.6 mg/mL BID
Number of subjects: 340

Group type: COMPARATOR
Intervention: Vehicle nasal spray
Number of subjects: 340
Study: 38440179

Group type: EXPERIMENTAL
Intervention: Houtou Jianweiling tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38440302

Group type: EXPERIMENTAL
Intervention: Super-bioavailability itraconazole (SUBA-itra)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional itraconazole (c-itra)
Number of subjects: 88
Study: 38440406

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Hassles frequency measured in the third trimester
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Uplifts intensity measured in the third trimester
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Hassles intensity measured in the third trimester
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Intensity ratio of hassles to uplifts reported in the third trimester
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Pregnancy experiences at baseline during early to mid-pregnancy
Number of subjects: 621
Study: 38440777

Group type: EXPERIMENTAL
Intervention: Support Through Remote Observation and Nutrition Guidance (STRONG) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 38440875

Group type: EXPERIMENTAL
Intervention: Loop recorder (Reveal LINQ)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Control group (no loop recorder)
Number of subjects: 956
Study: 38440889

Group type: EXPERIMENTAL
Intervention: Every Visit (n=339)
Number of subjects: 607

Group type: COMPARATOR
Intervention: <Every Visit (n=268)
Number of subjects: 607
Study: 38441108

Group type: EXPERIMENTAL
Intervention: New devices and techniques for early management of NCTH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive hemostatic resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control the bleeding source, resuscitate to maintain organ perfusion, and increase resistance against ischemia
Number of subjects: 0
Study: 38441437

Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GZ17-6.02 + Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knock down of ATM, AMPKα, ULK1, Beclin1 or ATG5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined knock down of HDACs1/2/3
Number of subjects: 0
Study: 38441576

Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV) 1.25 mg/kg plus Pembrolizumab 200 mg
Number of subjects: 121
Study: 38441657

Group type: EXPERIMENTAL
Intervention: Laparoscopic and open surgery for rectal cancer (part of COLOR II trial)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Interventions to reduce fatigue and pain
Number of subjects: 385
Study: 38441850

Group type: EXPERIMENTAL
Intervention: AbGn-107 at 1.0 mg/kg every 2 weeks (Q2W)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AbGn-107
Number of subjects: 39
Study: 38441854

Group type: EXPERIMENTAL
Intervention: 12 mg/kg/day cannabidiol (Epidyolex)
Number of subjects: 0
Study: 38441897

Group type: EXPERIMENTAL
Intervention: EXTRA-CVD intervention group
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297
Study: 38441919

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 2.5 mg + 100 mg placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg + 2.5 mg placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo 2.5 mg + 100 mg placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physical therapy (combined with all interventions)
Number of subjects: 36
Study: 38441939

Group type: EXPERIMENTAL
Intervention: 12-week Sprint-Intensity Interval Training (SIT) program, 3 tele-supervised sessions per week, 30 repeated sequences of 4 seconds of maximal arm exercise, with active recovery, warm-up, and cooldown periods (approximately 20 minutes total session).
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group continuing habitual activity for 12 weeks.
Number of subjects: 50
Study: 38442717

Group type: EXPERIMENTAL
Intervention: High-dose rivaroxaban regimen (HDRR, 20/15 mg)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Low-dose rivaroxaban regimen (LDRR, 15/10 mg)
Number of subjects: 1093
Study: 38442809

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Physician-recommended and conventional treatments
Number of subjects: 1689
Study: 38443074

Group type: EXPERIMENTAL
Intervention: ds-MCE
Number of subjects: 607

Group type: COMPARATOR
Intervention: OGD
Number of subjects: 607
Study: 38443077

Group type: EXPERIMENTAL
Intervention: Survey measuring the impact of the cardiac condition on specific life domains (e.g., daily activities, social and family relationships, hobbies, sexual life)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-4 for measuring anxiety and depression symptoms
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Qualitative content analysis of survey items evaluating experiences and preferences for improvements to the waiting experience
Number of subjects: 268
Study: 38443079

Group type: EXPERIMENTAL
Intervention: Provision of an e-cigarette starter kit and referral to stop smoking services (SSS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Professional panel recommendations for e-cigarette devices
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PPI lay panel feedback on e-cigarette devices
Number of subjects: 10
Study: 38443081

Group type: EXPERIMENTAL
Intervention: Standard care plus daily mobile phone text messages with instructions for outdoor walking and functional leg exercises.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study: 38443087

Group type: EXPERIMENTAL
Intervention: Women after pre-eclampsia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women after normotensive pregnancy
Number of subjects: 0
Study: 38443130

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Dyad gels (three additional arms in phase 2)
Number of subjects: 1104
Study: 38443333

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg orally, twice daily), Bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once every 3 weeks), Durvalumab (1.12 g intravenously, once every 3 weeks)
Number of subjects: 74
Study: 38443354

Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy for 8 weeks
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Subcortical functional connectivity (FC) score
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Replication analysis in independent sample (n = 74)
Number of subjects: 135
Study: 38443427

Group type: EXPERIMENTAL
Intervention: DNA-personalised dietary advice
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: DNA-personalised dietary advice via a self-guided app and wearable device
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control arm: standard care (NICE guidelines)
Number of subjects: 148
Study: 38443648

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 38443660

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 388
Study: 38443693

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 36
Study: 38443722

Group type: EXPERIMENTAL
Intervention: Oxygen-enhanced MRI (OE-MRI)
Number of subjects: 15
Study: 38443835

Group type: EXPERIMENTAL
Intervention: Opportunistic screening for COPD among hospitalized patients in contact with hospital social nurses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline clinical examination including spirometry and interviews regarding risk factors, socioeconomic conditions, and respiratory symptoms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-year follow-up assessment incorporating baseline data and register data.
Number of subjects: 0
Study: 38443858

Group type: EXPERIMENTAL
Intervention: COPD self-management application on smartphone and smartwatch for 6 months
Number of subjects: 34
Study: 38443879

Group type: EXPERIMENTAL
Intervention: 2.9 mm Narrow Diameter Implants (Ti-Zr alloy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3.3 mm Control Group Implants
Number of subjects: 40
Study: 38443944

Group type: EXPERIMENTAL
Intervention: Exercise group (physical-cognitive exercise 3 days/week, 3 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combined group (diet + physical-cognitive exercise)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet group (intermittent fasting 2 days/week, 3 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diet group and Combined group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All three intervention groups (diet, exercise, combined)
Number of subjects: 92
Study: 38443957

Group type: EXPERIMENTAL
Intervention: Self-administered at-home lung ultrasound (SAAH-LUS) with remote teleguidance
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Remote teleguidance by a physician
Number of subjects: 18
Study: 38443989

Group type: EXPERIMENTAL
Intervention: Fluoridated bottled water (0.7 mg/L F)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-fluoridated bottled water
Number of subjects: 200
Study: 38443992

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (Confident, Active, and Happy Youth)
Number of subjects: 21
Study: 38444034

Group type: EXPERIMENTAL
Intervention: MTX combined with TNF-α blocker certolizumab pegol (arm CZP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: MTX combined with IL-6R blocker tocilizumab (arm TCZ)
Number of subjects: 152

Group type: COMPARATOR
Intervention: MTX combined with prednisolone (arm ACT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: MTX combined with CTLA-4Ig abatacept (arm ABA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Baseline urinary eicosanoid levels
Number of subjects: 152

Group type: COMPARATOR
Intervention: Urinary eicosanoid levels
Number of subjects: 152
Study: 38444064

Group type: EXPERIMENTAL
Intervention: Oral probiotics (5 billion colony-forming units each)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38444312

Group type: EXPERIMENTAL
Intervention: Hybrid-closed loop (HCL) therapy from diagnosis of T1D
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 51
Study: 38444316

Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop Systems
Number of subjects: 0
Study: 38444429

Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 1 (DL1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 3 (DL3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 4 (DL4)
Number of subjects: 12
Study: 38444519

Group type: EXPERIMENTAL
Intervention: Once-daily prolonged-release tacrolimus (Envarsus) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 38444629

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable glucagon (IG)
Number of subjects: 0
Study: 38444861

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination combined with carboplatin/paclitaxel chemotherapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel chemotherapy
Number of subjects: 7
Study: 38444875

Group type: EXPERIMENTAL
Intervention: Power training (24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (24 weeks)
Number of subjects: 60
Study: 38445250

Group type: EXPERIMENTAL
Intervention: Deep-structure culturally tailored healthy eating text messages for 2 months, reinforced for 2 subsequent months.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surface-level messages based on USDA MyPlate in Spanish (control group).
Number of subjects: 75
Study: 38445295

Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg
Number of subjects: 17